Please login to the form below

Not currently logged in
Email:
Password:

Dr Olivier Danos joins TxCell scientific advisory board

He currently serves as cell and gene therapy SVP at Biogen

TxCell Dr Olivier DanosFrench biotechnology company TxCell has appointed Biogen's Dr Olivier Danos to its scientific advisory board.

Since 2014, Dr Danos has served as senior vice president of cell and gene therapy at Biogen, leading its research group to develop new technologies for gene transfer and genome engineering.

Before to taking up this role in 2011, Dr Danos was Kadmon Pharmaceutical's senior vice president for molecular science, synthetic biology and gene regulation, where he led the creation of its gene therapy and technology platforms.

He has also served as director of the Gene Therapy Consortium at University College London, scientific director of Généthon, and senior research director for France's National Centre for Scientific Research (CNRS).

Arnoud Foussat, chief scientific officer at TxCell, said: “Dr Olivier Danos has pioneered technologies of central importance in the field of gene therapy and genome editing.

“He is another significant addition to our scientific advisory board, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors.

“We are looking forward to their insights and advice on our current and future research and development programmes targeting severe chronic autoimmune and inflammatory diseases.”

1st September 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Stick or Twist? Healthcare brands in a (post) COVID-19 world
...
Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic
...
Lockdown entertainment or healthcare revolution? The role of video games in healthcare
...